Zealand Pharma's GLP-1 Candidate Achieves 17% Weight Loss in Late-Stage Trial
Zealand Pharma (ZLDPF) announced that its GLP-1 candidate, survodutide, developed with Boehringer Ingelheim, met primary endpoints in a late-stage trial, achieving up to 17% weight loss. The positive trial results could have significant implications for the obesity treatment market.
Topics: clinical trials drug development GLP-1 pharmaceuticals weight loss